openPR Logo
Press release

Dengue Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

03-21-2017 04:23 PM CET | Health & Medicine

Press release from: CMI Market Report

Dengue Vaccines Market - Global Industry Insights, Trends,

Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by controlling the vectors being borne. Severe dengue was discovered in the 1950s during dengue epidemics in Philippines and Thailand. The disease has since spread to Asian and Latin America countries and is one of the leading causes of hospitalization and deaths among children and adults in these regions.

To know about the assumptions considered for the study, Download the PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/23

Prevalent Scenario in the Global Dengue Vaccines Market

Member states in three of the WHO regions regularly report the annual number of dengue cases. These statistic suggest that the number of dengue cases increased from 2.2 million in 2010 to 3.2 million in 2015. The actual number remains underreported. One recent estimate by Bhatt et al., (also quoted by the WHO) mentions that there are around 390 million dengue cases worldwide each year, with number of cases reported increasing each year. In 2015, 2.35 million cases of dengue were reported in the Americas alone, of which 10,200 cases were diagnosed as severe dengue that led to 1,181 deaths. Dengue is a pertinent health issue affecting people across South America, Europe, and Asia. A large number of dengue outbreaks were reported worldwide in 2015, with over 169,000 cases in the Philippines and over 111,000 suspected cases of dengue in Malaysia. This was a staggering 59.5% and 16% increase respectively in the number of cases compared to that in 2014. The global dengue vaccines market therefore, offers lucrative growht opportunities for vaccine manufacturers.

Dengvaxia – the only approved product in the global dengue vaccines market

Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the world’s first licensed vaccine for prevention of dengue. It is a tetravalent dengue vaccine that prevents the disease from all four dengue viruses in people aged 9 to 45 years. Sanofi launched the world’s first public dengue vaccination program in the Philippines (2016), followed by Brazil. Dengvaxia is approved in 10 endemic countries worldwide, namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador, Costa Rica, Indonesia, Peru, and Guatemala. The global dengue vaccines market is thus, expected to expand with growing market approvals.

India is however taking a precautionary approach in approving this vaccine due to lack of studies among the population in the country. A scientist in India has developed a dengue vaccine that was successfully tested in monkeys. If successful in human trials, this could be a breakthrough invention for prevention of dengue among the populace in the country. Moreover, various philanthropists and global organizations are investing in developing vaccines for malaria and dengue.

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/ongoing-insight/dengue-vaccines-market-23

Dengue Vaccines Market Outlook – Research Pipeline

There are approximately five vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Also, technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies. In September 2016, Takeda announced the beginning of the phase 3 clinical trials of its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue virus strains.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dengue Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024 here

News-ID: 475942 • Views: 1630

More Releases from CMI Market Report

ENT Chairs Market – Global Industry Insights, Trends
ENT is an area of medicine dealing with treatment of human body parts namely ear, nose, and throat (ENT) and few related areas such as neck and face. The medical disorders treated by ENT physicians include chronic ear infection, sinusitis, snoring, sleep apnea, hearing loss, allergies, hay fever, swallowing disorders, nosebleeds, hoarseness, dizziness and neck cancer. Ear, nose and throat specialists or otolaryngologists have specific tools for treating patients well
Global Respiratory Inhalers Market to Surge Past US$ 38.8 Billion by 2024
Respiratory Inhalers – Getting the Wind Back in Your Lungs Respiratory diseases such as bronchitis, asthma, allergic rhinitis, pneumonia and sinusitis can significantly curtail the physical activities of the individual. The symptoms associated with both mild and severe manifestations of these respiratory conditions include coughing, wheezing, chest pain, respiratory distress, shortness of breath, congestion, and even death in severe cases. These conditions lead to substantial morbidity and causes large cost of
Dental Equipment Market is Expected to Expand at a CAGR of 4.7% During the Forec …
The Global Dental Equipment Market was valued at US$ 6,342.3 million in 2015 and is projected to expand at a CAGR of 4.7% during 2016–2024, according to a new report published by Coherent Market Insights.Increasing prevalence of poor oral health is increasing patient visits to dental clinics and in turn, is increasing demand for dental equipment. Changing eating habits has led to increase in dental caries and infection among children and
Medical Electrodes Market - Global Industry Insights Analysis, Size, Share, Grow …
Increasing prevalence of cardiology and neurological diseases among the population drives growth of the global medical electrodes market According to The World Health Organization’s estimates in 2012, the global geriatric population was pegged at 901 million in 2015, which is expected to increase over 2 billion by 2050. Geriatric population is highly susceptible to various cardiology and neurological diseases, thus creating a need for early diagnosis which can be achieved using

All 5 Releases


More Releases for Dengue

Dengue Fever - Pipeline Review, H1 2018
HTF Market Report released a new research document of 158 pages on industry titled as 'Dengue Fever - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as GeneSegues , GlaxoSmithKline , Globavir Biosciences , Immunotope etc The report will help you gain market insights, future trends and growth prospects for forecast period. Request a sample report @
Dengue Fever Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H1 2017, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape. Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It
Dengue Vaccines Market - Global Insights, 2016-2024
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by
Dengue Vaccines Market - Global Industry Analysis 2024
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by
Dengue Vaccines Market to Grow Globally
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by
Dengue Vaccines Market - Global Industry Analysis 2024
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by